PDPia Dosenovic

Pia Dosenovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pia Dosenovic has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AID and TET2 cooperate to demethylate Irf4 for plasma cell fate in germinal center B cells

    by Minghui He, Roberta D’AUlerio, Lia G. Pinho, Evangelos Doukoumopoulos, Tracer Yong, Rhaissa C. Vieira, Mariana M.S. Oliveira, Laura Eiben, Manon Termote, Rômulo G. Galvani, et al.

    Activation-induced cytidine deaminase (AID) is essential for B cell affinity maturation. We investigated why AID deficiency gives rise to giant germinal centers (GCs) using the AIDR112H mouse model that is devoid of AID activity. The increased GC response was associated with accumulation of GC B cells in the light zone in immunized AIDR112H mice. AIDR112H GC B cells had reduced capacity to upregulate IRF4 to initiate plasma cell differentiation, leading to accumulation of a transitional GC population with reduced GL7 expression. Genetic introduction of a high-affinity B cell receptor was unable to restore plasma cell differentiation of AIDR112H B cells, while ectopic expression of catalytically active AID rescued plasma cell generation. AID and ten-eleven translocation 2 (TET2) synergistically facilitated demethylation of the Irf4 promoter/enhancer, and this was impeded in AIDR112H cells. These data reveal a B cell–intrinsic mechanism that governs the plasma cell fate decision through epigenetic remodeling mediated by AID in cooperation with TET2.


  • Open Access

    Antigen affinity and site of immunization dictate B cell recall responses

    by Manon Termote, Rafael C. Marques, Erik Hyllner, Mariia V. Guryleva, Mirthe Henskens, Andreas Brutscher, Isabel J.L. Baken, Xaquin Castro Dopico, Adria Dalmau Gasull, Ben Murrell, et al.


  • Open Access

    Antigen affinity and site of immunization dictate B cell recall responses

    by M. Termote, R. C. Marques, E. Hyllner, M. V. Guryleva, M. Henskens, A. Brutscher, I.J.L. Baken, X. Castro Dopico, A. Dalmau Gasull, B. Murrell, et al.

    Summary: Protective antibodies against HIV-1 require unusually high levels of somatic hypermutations (SHMs) introduced in germinal centers (GCs). To achieve this, a sequential vaccination approach was proposed. Using HIV-1 antibody knock-in mice with fate-mapping genes, we examined if antigen affinity affects the outcome of the B cell recall response. Compared to high affinity boost, low affinity boost resulted in decreased numbers of memory-derived B cells in secondary GCs, but with higher average SHM, indicating an affinity threshold for memory B cells to enter secondary GCs. Upon boosting local LNs, numbers of residual GC B cells increased independent on antigen affinity, while average SHM decreased. Our results demonstrate that antigen affinity and location of the boost affect the outcome of the B cell recall response. These results can help guide the design of vaccine immunogens aiming to selectively engage specific B cell clones for further SHM diversification.

  • Open Access

    Anti-idiotypic antibodies elicit anti-HIV-1–specific B cell responses

    by Pia Dosenovic, Anna-Klara Pettersson, Abigail Wall, Eddy S. Thientosapol, Junli Feng, Connor Weidle, Komal Bhullar, Ervin E. Kara, Harald Hartweger, Joy A. Pai, et al.

    Human anti-HIV-1 broadly neutralizing antibodies (bNAbs) protect against infection in animal models. However, bNAbs have not been elicited by vaccination in diverse wild-type animals or humans, in part because B cells expressing the precursors of these antibodies do not recognize most HIV-1 envelopes (Envs). Immunogens have been designed that activate these B cell precursors in vivo, but they also activate competing off-target responses. Here we report on a complementary approach to expand specific B cells using an anti-idiotypic antibody, iv8, that selects for naive human B cells expressing immunoglobulin light chains with 5–amino acid complementarity determining region 3s, a key feature of anti-CD4 binding site (CD4bs)–specific VRC01-class antibodies. In mice, iv8 induced target cells to expand and mature in the context of a polyclonal immune system and produced serologic responses targeting the CD4bs on Env. In summary, the results demonstrate that an anti-idiotypic antibody can specifically recognize and expand rare B cells that express VRC01-class antibodies against HIV-1.


  • Open Access

    Antigen-specific humoral immune responses by CRISPR/Cas9-edited B cells

    by Harald Hartweger, Andrew T. McGuire, Marcel Horning, Justin J. Taylor, Pia Dosenovic, Daniel Yost, Anna Gazumyan, Michael S. Seaman, Leonidas Stamatatos, Mila Jankovic, et al.

    A small number of HIV-1 infected individuals develop broadly neutralizing-antibodies to the virus (bNAbs). These antibodies are protective against infection in animal models. However, they only emerge 1 - 3 years after infection, and show a number of highly unusual features including exceedingly high levels of somatic mutations. It is therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible. Here we show that mature, primary mouse and human B cells can be editedin vitrousing CRISPR/Cas9 to express mature bNAbs from the endogenousIghlocus. Moreover, edited B cells retain the ability to participate in humoral immune responses. Immunization with cognate antigen in wild type mouse recipients of edited B cells elicits bNAb titers that neutralize HIV-1 at levels associated with protection against infection. This approach enables humoral immune responses that may be difficult to elicit by traditional immunization.One-sentence summary: B cells edited by CRISPR/Cas9 to produce antibodies participate in humoral immune reactions and secrete neutralizing serum titers of anti-HIV bNAbs.

  • Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity

    by Pia Dosenovic, Ervin E. Kara, Anna-Klara Pettersson, Andrew T. McGuire, Matthew Gray, Harald Hartweger, Eddy S. Thientosapol, Leonidas Stamatatos, Michel C. Nussenzweig

    Significance: An essential requirement for an HIV vaccine is to elicit antibodies to conserved regions of the spike protein (i.e., Env) because these antibodies can protect against infection. Although broadly neutralizing antibodies develop naturally in rare individuals after prolonged HIV infection, eliciting them by vaccination has only been possible in artificial knock-in mouse models in which the number of B cells expressing the antibody precursor is superphysiologic. To understand the relationship among precursor frequency, antigen affinity, and germinal center recruitment, we have performed adoptive transfer experiments in which fixed numbers of precursor cells are engrafted in WT mice. Our results provide a framework for an understanding of how precursor frequency and antigen affinity shape humoral immunity to HIV.


  • Open Access

    Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen binding affinity

    by Pia Dosenovic, Ervin E. Kara, Anna-Klara Pettersson, Andrew McGuire, Matthew Gray, Harald Hartweger, Eddy S. Thientosapol, Leonidas Stamatatos, Michel C. Nussenzweig

    The discovery that humans can produce potent broadly neutralizing antibodies (bNAbs) to several different epitopes on the HIV-1 spike has reinvigorated efforts to develop an antibody based HIV-1 vaccine. Antibody cloning from single cells revealed that nearly all bNAbs show unusual features that could help explain why it has not been possible to elicit them by traditional vaccination, and instead that it would require a sequence of different immunogens. This idea is supported by experiments with genetically modified immunoglobulin knock-in mice. Sequential immunization with a series of specifically designed immunogens was required to shepherd the development of bNAbs. However, knock-in mice contain super-physiologic numbers of bNAb precursor expressing B cells and therefore how these results can be translated to a more physiologic setting remains to be determined. Here we make use of adoptive transfer experiments using knock-in B cells that carry a synthetic intermediate in the pathway to anti-HIV-1 bNAb development to examine how the relationship between B cell receptor affinity and precursor frequency affects germinal center B cell recrutiment and clonal expansion. Immunization with soluble HIV-1 antigens can recruit bNAb precursor B cells to the germinal center when there are as few as 10 such cells per mouse. However, at low precursor frequencies the extent of clonal expansion is directly proportional to the affinity of the antigen for the B cell receptor, and recruitment to germinal centers is variable and dependent on re-circulation. Significance statement: An essential requirement for an HIV-vaccine is to elicit antibodies to conserved regions of the spike protein (Env) becasue these antibodies can protect against infection. Although broadly neutralizing antibodies develop naturally in rare individuals after prolongued HIV infection, eliciting them by vaccination has only been possible in artificial knock-in mouse models wherein the number of B cells expressing the antibody precursor is super-physiologic. To understand the relationship between precursor frequency, antigen affinity and germinal center recruitment we have performed adoptive transfer experiments in which fixed numbers of precursor cells are engrafted in wild type mice. Our results provide a framework for understanding how precursor frequency and antigen affinity shape humoral immunity to HIV.


  • Altered Marginal Zone B Cell Selection in the Absence of IκBNS

    by Monika Ádori, Gabriel K. Pedersen, Csaba Ádori, Elina Erikson, Sharesta Khoenkhoen, Julian M. Stark, Jin Huk Choi, Pia Dosenovic, Mikael C I Karlsson, Bruce Beutler, et al.

    Marginal zone (MZ) B cells reside in the splenic MZ and play important roles in T cell–independent humoral immune responses against blood-borne pathogens. IκBNS-deficient bumble mice exhibit a severe reduction in the MZ B compartment but regain an MZ B population with age and, thus, represent a valuable model to examine the biology of MZ B cells. In this article, we characterized the MZ B cell defect in further detail and investigated the nature of the B cells that appear in the MZ of aged bumble mice. Flow cytometry analysis of the splenic transitional B cell subsets demonstrated that MZ B cell development was blocked at the transitional-1 to transitional-2–MZ precursor stage in the absence of functional IκBNS. Immunohistochemical analysis of spleen sections from wild-type and bumble mice revealed no alteration in the cellular MZ microenvironment, and analysis of bone marrow chimeras indicated that the MZ B cell development defect in bumble mice was B cell intrinsic. Further, we demonstrate that the B cells that repopulate the MZ in aged bumble mice were distinct from age-matched wild-type MZ B cells. Specifically, the expression of surface markers characteristic for MZ B cells was altered and the L chain Igλ+ repertoire was reduced in bumble mice. Finally, plasma cell differentiation of sorted LPS-stimulated MZ B cells was impaired, and aged bumble mice were unable to respond to NP-Ficoll immunization. These results demonstrate that IκBNS is required for an intact MZ B cell compartment in C57BL/6 mice.


  • Top Cited Papers
    Open Access

    Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

    by Max Medina-Ramírez, Fernando Garces, Amelia Escolano, Patrick Skog, Steven W. de Taeye, Ivan Del Moral-Sanchez, Andrew T. McGuire, Anila Yasmeen, Anna-Janina Behrens, Gabriel Ozorowski, et al.

    Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward an effective vaccine. A critical step in this process is the activation of naive B cells expressing germline (gl) antibody precursors that have the potential to evolve into bNAbs. Here, we reengineered the BG505 SOSIP.664 glycoprotein to engage gl precursors of bNAbs that target either the trimer apex or the CD4-binding site. The resulting BG505 SOSIP.v4.1-GT1 trimer binds multiple bNAb gl precursors in vitro. Immunization experiments in knock-in mice expressing gl-VRC01 or gl-PGT121 show that this trimer activates B cells in vivo, resulting in the secretion of specific antibodies into the sera. A crystal structure of the gl-targeting trimer at 3.2-Å resolution in complex with neutralizing antibodies 35O22 and 9H+109L reveals a native-like conformation and the successful incorporation of design features associated with binding of multiple gl-bNAb precursors.


  • Open Access

    Progress toward active or passive HIV-1 vaccination

    by Amelia Escolano, Pia Dosenovic, Michel C. Nussenzweig

    AIDS is a preventable disease. Nevertheless, according to UNAIDS, 2.1 million individuals were infected with HIV-1 in 2015 worldwide. An effective vaccine is highly desirable. Most vaccines in clinical use today prevent infection because they elicit antibodies that block pathogen entry. Consistent with this general rule, studies in experimental animals have shown that broadly neutralizing antibodies to HIV-1 can prevent infection, suggesting that a vaccine that elicits such antibodies would be protective. However, despite significant efforts over the last 30 years, attempts to elicit broadly HIV-1 neutralizing antibodies by vaccination failed until recent experiments in genetically engineered mice were finally successful. Here, we review the key breakthroughs and remaining obstacles to the development of active and passive HIV-1 vaccines.